- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07544589
Et fase 1-studie, der evaluerer DISP-10 hos deltagere med fremskredne mavetarm-kræftformer
Et fase 1-studie til evaluering af sikkerheden og effektiviteten af DISP-10 hos deltagere med fremskredne gastrointestinale kræftformer
This is a Phase 1, multicenter, open-label study of DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (ide-cel, BCMA-directed chimeric antigen receptor [CAR] T), in adult participants with advanced gastrointestinal (GI) cancers.
The study will consist of 2 parts: dose-escalation (Part 1) and dose-expansion (Part 2). Part 1 of the study will evaluate the safety and tolerability of increasing dose levels of DISP-10 to establish the recommended dose for expansion (RDE); Part 2 will evaluate the safety and efficacy of DISP-10 in participants treated at the RDE.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Dispatch Clinical
- Telefonnummer: (215) 792-4699
- E-mail: clinicaltrials@dispatchbio.com
Studiesteder
-
-
California
-
Duarte, California, Forenede Stater, 91010
- Rekruttering
- City of Hope
-
Newport Beach, California, Forenede Stater, 92663
- Rekruttering
- Hoag Memorial Hospital Presbyterian
-
-
Florida
-
Tampa, Florida, Forenede Stater, 33612
- Rekruttering
- Moffitt Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Rekruttering
- Dana-Farber Cancer Institute
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45267
- Rekruttering
- University of Cincinnati Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- Ikke rekrutterer endnu
- Tennessee Oncology
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84112
- Rekruttering
- Huntsman Cancer Institute
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
- Histologically confirmed advanced or metastatic esophageal, gastroesophageal junction, gastric adenocarcinoma, colorectal adenocarcinoma, or biliary tract carcinoma
- Measurable disease according to RECIST v1.1 and at least 1 additional site of disease amenable to biopsy
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Aged ≥18 years at time of signing informed consent
- Adequate organ function
Key Exclusion Criteria:
- Previous solid organ or hematopoietic cell transplant
- Evidence of rapid disease progression, defined as radiographic or clinical progression within 3 months of the most recent prior line of therapy
- Known history of hepatitis B or HIV infection
- Previous or concurrent malignancy except if curatively treated more than 3 years prior to enrollment
- Known active central nervous system (CNS) metastases
- Clinically significant pleural or pericardial effusion or peritoneal carcinomatosis
- Active treatment with antiviral agents
- History of severe hypersensitivity to fludarabine or cyclophosphamide
- Prior therapies/treatments with oncolytic viruses or T cell derived cellular therapy
Additional criteria apply and should be discussed with the study site.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: DISP-10
Participants will receive DV-10 in combination with ide-cel. Lymphodepleting chemotherapy (fludarabine and cyclophosphamide) will be administered a few days prior to ide-cel. |
Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce ide-cel. During ide-cel production, participants may receive bridging therapy for disease control per Investigator discretion. DV-10 administration will be followed by lymphodepleting chemotherapy (fludarabine and cyclophosphamide) and subsequent ide-cel administration. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Treatment Emergent Adverse Events (TEAEs)
Tidsramme: 90 days (2 years for related Serious Adverse Events)
|
Graded using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) v6.0 |
90 days (2 years for related Serious Adverse Events)
|
|
Incidence of Dose Limiting Toxicities (DLTs) [PART 1]
Tidsramme: 28 days
|
Graded using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) v6.0 |
28 days
|
|
Identification of the Recommended Dose for Expansion (RDE) [PART 1]
Tidsramme: Up to 2 years
|
To select the Recommended Dose for Expansion (RDE) for Part 2 |
Up to 2 years
|
|
Overall response rate (ORR) [PART 2]
Tidsramme: Up to 2 years
|
Confirmed complete response (CR) or partial response (PR), per RECIST v1.1 |
Up to 2 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall response rate (ORR) [PART 1]
Tidsramme: Up to 2 years
|
Confirmed CR or PR, per RECIST v1.1 |
Up to 2 years
|
|
Disease control rate (DCR)
Tidsramme: Up to 2 years
|
Proportion of participants with CR, PR, or stable disease per RECIST v1.1 |
Up to 2 years
|
|
Duration of response (DOR)
Tidsramme: Up to 2 years
|
Time from CR or PR to radiographic progression or death |
Up to 2 years
|
|
Progression Free Survival (PFS)
Tidsramme: Up to 2 years
|
Time from ide-cel administration to disease progression or death, whichever occurs first |
Up to 2 years
|
|
Overall survival (OS)
Tidsramme: Up to 15 years
|
Time from ide-cel administration to death |
Up to 15 years
|
|
Time to response (TTR)
Tidsramme: Up to 2 years
|
Time from ide-cel administration to the first documentation of objective tumor response |
Up to 2 years
|
|
Cellular kinetics (CK) of ide-cel
Tidsramme: Up to 2 years
|
Measurement of ide-cel CK in the blood |
Up to 2 years
|
|
Pharmacokinetics of DV-10 - Cmax
Tidsramme: Up to 2 years
|
Maximum concentration in blood |
Up to 2 years
|
|
Pharmacokinetics of DV-10 - Tmax
Tidsramme: Up to 2 years
|
Time to maximum concentration in blood |
Up to 2 years
|
|
Pharmacokinetics of DV-10 - AUC
Tidsramme: Up to 2 years
|
Area under the blood concentration curve |
Up to 2 years
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Tarmsygdomme
- Infektioner
- Virussygdomme
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Intestinale neoplasmer
- Endetarmssygdomme
- Tyktarmssygdomme
- DNA-virusinfektioner
- Kolorektale neoplasmer
- Gastrointestinale neoplasmer
- Adenoviridae infektioner
- Adenocarcinom i spiserøret
Andre undersøgelses-id-numre
- DISP-10-101
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .